Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 16

1.

Targeting the SH2-kinase interface in Bcr-Abl inhibits leukemogenesis.

Grebien F, Hantschel O, Wojcik J, Kaupe I, Kovacic B, Wyrzucki AM, Gish GD, Cerny-Reiterer S, Koide A, Beug H, Pawson T, Valent P, Koide S, Superti-Furga G.

Cell. 2011 Oct 14;147(2):306-19. doi: 10.1016/j.cell.2011.08.046.

2.

Molecular and cellular bases of chronic myeloid leukemia.

Chen Y, Peng C, Li D, Li S.

Protein Cell. 2010 Feb;1(2):124-32. doi: 10.1007/s13238-010-0016-z. Epub 2010 Feb 6. Review.

3.

Important therapeutic targets in chronic myelogenous leukemia.

Kantarjian HM, Giles F, Quintás-Cardama A, Cortes J.

Clin Cancer Res. 2007 Feb 15;13(4):1089-97. Review.

4.

Suppression of autophagy by BCR/ABL.

Calabretta B, Salomoni P.

Front Biosci (Schol Ed). 2012 Jan 1;4:453-60. Review.

PMID:
22202070
5.

Targeting the kinase activity of the BCR-ABL fusion protein in patients with chronic myeloid leukemia.

Giles FJ, Cortes JE, Kantarjian HM.

Curr Mol Med. 2005 Nov;5(7):615-23. Review.

PMID:
16305488
6.

Mutated tyrosine kinases as therapeutic targets in myeloid leukemias.

Sattler M, Scheijen B, Weisberg E, Griffin JD.

Adv Exp Med Biol. 2003;532:121-40. Review.

PMID:
12908554
7.

Mechanisms of resistance to BCR-ABL and other kinase inhibitors.

Lamontanara AJ, Gencer EB, Kuzyk O, Hantschel O.

Biochim Biophys Acta. 2013 Jul;1834(7):1449-59. doi: 10.1016/j.bbapap.2012.12.009. Epub 2012 Dec 28. Review.

PMID:
23277196
8.

Chronic myeloid leukemia and second-generation tyrosine kinase inhibitors: when, how, and which one?

Jabbour E, Kantarjian H, Cortes J.

Semin Hematol. 2010 Oct;47(4):344-53. doi: 10.1053/j.seminhematol.2010.06.002. Review.

PMID:
20875551
9.

Practical advice for determining the role of BCR-ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia.

Jabbour E, Branford S, Saglio G, Jones D, Cortes JE, Kantarjian HM.

Cancer. 2011 May 1;117(9):1800-11. doi: 10.1002/cncr.25717. Epub 2010 Nov 29. Review. Erratum in: Cancer. 2011 Aug;117(15):3535.

10.

Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia.

Weisberg E, Manley PW, Cowan-Jacob SW, Hochhaus A, Griffin JD.

Nat Rev Cancer. 2007 May;7(5):345-56. Review.

PMID:
17457302
11.

Pushing the limits of targeted therapy in chronic myeloid leukaemia.

O'Hare T, Zabriskie MS, Eiring AM, Deininger MW.

Nat Rev Cancer. 2012 Jul 24;12(8):513-26. doi: 10.1038/nrc3317. Review. Erratum in: Nat Rev Cancer. 2012 Dec;12(12):886.

PMID:
22825216
12.

Structure and dynamic regulation of Abl kinases.

Panjarian S, Iacob RE, Chen S, Engen JR, Smithgall TE.

J Biol Chem. 2013 Feb 22;288(8):5443-50. doi: 10.1074/jbc.R112.438382. Epub 2013 Jan 11. Review.

13.

Development of a Predictive Pharmacophore Model and a 3D-QSAR Study for an in silico Screening of New Potent Bcr-Abl Kinase Inhibitors.

Vrontaki E, Melagraki G, Voskou S, Phylactides MS, Mavromoustakos T, Kleanthous M, Afantitis A.

Mini Rev Med Chem. 2017;17(3):188-204. Review.

PMID:
28143387
14.

Rac GTPases as key regulators of p210-BCR-ABL-dependent leukemogenesis.

Thomas EK, Cancelas JA, Zheng Y, Williams DA.

Leukemia. 2008 May;22(5):898-904. doi: 10.1038/leu.2008.71. Epub 2008 Mar 20. Review.

15.

Tyrosine kinase gene fusions in cancer: translating mechanisms into targeted therapies.

Medves S, Demoulin JB.

J Cell Mol Med. 2012 Feb;16(2):237-48. doi: 10.1111/j.1582-4934.2011.01415.x. Review.

16.

The growing arsenal of ATP-competitive and allosteric inhibitors of BCR-ABL.

Hantschel O, Grebien F, Superti-Furga G.

Cancer Res. 2012 Oct 1;72(19):4890-5. doi: 10.1158/0008-5472.CAN-12-1276. Epub 2012 Sep 21. Review.

Supplemental Content

Support Center